Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00429065|
Recruitment Status : Unknown
Verified January 2007 by Instituto Nacional de Cancerologia de Mexico.
Recruitment status was: Recruiting
First Posted : January 31, 2007
Last Update Posted : January 31, 2007
|Condition or disease||Intervention/treatment||Phase|
|Non-Hodgkin Lymphoma||Drug: Rituximab||Phase 4|
Treatment with rituximab and chemotherapy (R-CHOP)is the accepted treatment for young patients with diffuse large B cell Non-Hodgkin's Lymphoma. However not every patient benefits with this expensive therapy. Recent data suggest that patients with BCL-6 negative lymphoma are more sensitive to Rituximab therapy. It is also known that patients with high-intermediate and high IPI risk does not benefit form standard three weekly CHOP chemotherapy.
In this study we intend to define a subgroup of patients in whom this therapy will be of maximum benefit.
We will prospectively treat a group of patients with the following characteristics:
< 60 years old low and low intermediate IPI risk BCL-6 negative B-cell NHL Treatment regimen: R-CHOP (standard dosis) for 8 cycles
|Study Type :||Observational|
|Estimated Enrollment :||30 participants|
|Observational Model:||Defined Population|
|Official Title:||Selection of Young Patients (< 61 Years), With Good Prognosis Diffuse Large B Cell Lymphoma, According to the Immunophenotype (BCL-6 Negative) to be Treated With Chemoimmunotherapy, With R-CHOP. A Pilot Study.|
|Study Start Date :||January 2007|
|Estimated Study Completion Date :||January 2007|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00429065
|Contact: Silvia Rivas-Vera, MD||56 28 04 firstname.lastname@example.org|
|Contact: Pedro Sobrevilla-Calvo, MD||56 28 04 email@example.com|
|Instituto Nacional de Cancerologia||Recruiting|
|Mexico City, D.f., Mexico, 14080|
|Principal Investigator:||Pedro Sobrevilla-Calvo, MD||Instituto Nacional de Cancerologia Mexico|
|Principal Investigator:||Silvia Rivas-Vera, MD||Instituto Nacional de Cancerologia Mexico|